Abstract:2 Objectives: Checkpoint immunotherapy treatments are showing great promise for cancer patients; however, the mechanisms and predictors of response are still largely mysteries, especially for CTLA-4-targeted treatments, which have particularly heterogeneous response patterns. Imaging of these immunotherapy targets using positron emission tomography (PET) can allow for noninvasive monitoring of their dynamic expression and biodistribution, and may allow for patient stratification in the future. Therefore, two tracers targeting human CTLA-4, one a full antibody and the other a F(ab’)2 fragment, were radiolabeled with 64Cu and validated in humanized mouse models. Methods: Ipilimumab was enzymatically digested to develop ipilimumab-F(ab’)2, and both the intact antibody and the fragment were conjugated with NOTA to chelate 64Cu for PET. Both tracers maintained their specificity for activated CTLA-4+ T-cells in vitro. The tracers were administered to both control NBSGW mice and humanized mice (PBL mice, which were engrafted with human peripheral blood lymphocytes), and PET was conducted out to 48 h post-injection. The onset of graft-versus-host disease in these humanized mice causes their salivary glands to dysfunction and sequestration of the foreign cells there, providing a localized site for exploration of CTLA-4+ tissue uptake. PET region-of-interest analysis, ex vivo biodistribution studies, and tissue staining were used to confirm that the tracers specifically accumulated in CTLA-4+ tissues. Results: Following intravenous injection of the respective tracers (n=3-5 per group), specific uptake was noted in the salivary gland tissues of the humanized mice. This uptake, as a result of graft-versus-host disease onset, was proven to be due to the presence of human T-cells through staining of the tissues for human CD3 and CTLA-4. 64Cu-NOTA-ipilimumab demonstrated the highest absolute uptake in the salivary glands of PBL mice, peaking at 7.00 ± 2.19 %ID/g, 24 h post-injection. In contrast, 64Cu-NOTA-ipilimumab-F(ab’)2 uptake was at 2.40 ± 0.86 %ID/g at the same time point. However, the F(ab’)2 agent cleared from circulation much more quickly than the intact antibody, providing higher salivary gland-to-blood ratios, which reached 1.78 ± 0.72 at 48 h post-injection, compared to 64Cu-NOTA-ipilimumab at 1.19 ± 0.49. Comparison with a nonspecific IgG, with a salivary gland-to-blood ratio of only 0.34 ± 0.08, verified the specificity of the salivary gland uptake with the targeted tracers. Uptake of the tracers in the salivary glands of control mice, and the nonspecific tracer in the PBL mice, was lower than that of the related targeted tracers at all imaging time points. Ex vivo studies verified all the trends found through PET analysis. Conclusions: PET imaging with both 64Cu-NOTA-ipilimumab and 64Cu-NOTA-ipilimumab-F(ab’)2 was able to localize CTLA-4+ tissues. These tracers may thus help elucidate the mechanisms of response to, and possibly toxicity from, CTLA-4-targeted checkpoint immunotherapy treatments.

Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models

Chemistry-Enabled Intercellular Enzymatic Labeling for Monitoring the Immune Effects of Cytotoxic T Lymphocytes In Vivo

Development of a Radiotracer for PET Imaging of the SNAP Tag.

Metabolic Radiolabeling and in Vivo PET Imaging of Cytotoxic T Lymphocytes to Guide Combination Adoptive Cell Transfer Cancer Therapy

Shortwave-Infrared-Emitting Nanoprobes for CD8 Targeting and In Vivo Imaging of Cytotoxic T Cells in Breast Cancer

Imaging CTLA-4+T-cells in Humanized Mouse Models

Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo

In Vivo Magnetic Resonance Imaging of CD8+ T Lymphocytes Recruiting to Glioblastoma in Mice

Antibody and Fragment-Based PET Imaging of CTLA-4+ T-cells in Humanized Mouse Models.

Spatiotemporal Tracking of Brain-Tumor-Associated Myeloid Cells in Vivo through Optical Coherence Tomography with Plasmonic Labeling and Speckle Modulation

ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer

In vivo imaging of nanoparticle-labeled CAR T cells

Specific imaging of CD8 + T-Cell dynamics with a nanobody radiotracer against human CD8β

Abstract 4178: Non-invasive shortwave infrared imaging of cytotoxic T lymphocyte infiltration for monitoring responses to combination immunotherapy and chemotherapy

ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents

Quantitative radio-thin-layer chromatography and positron emission tomography studies for measuring streptavidin transduced chimeric antigen receptor T cells

Dynamic Tracing Of Immune Cells In An Orthotopic Gastric Carcinoma Mouse Model Using Near-Infrared Fluorescence Live Imaging

Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes

In Vivo MR Imaging of Glioma Recruitment of Adoptive T-Cells Labeled with NaGdF4 -TAT Nanoprobes.

NIRF/PET Imaging of Γδ T Cells Via Metabolic Glycoengineering and Bioorthogonal Labeling

High-efficiency magnetophoretic labelling of adoptively-transferred T cells for longitudinal in vivo Magnetic Particle Imaging